SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy

Inhibition of the NEDD8-activating enzyme (NAE), the key E1 enzyme in the neddylation cascade, has been considered an attractive anticancer strategy with the discovery of the first-in-class NAE inhibitor, MLN4924. In this study, we identified SOMCL-19-133 as a highly potent, selective, and orally av...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Li-Na, Xiong, Chaodong, Cheng, Yong-Jun, Song, Shan-Shan, Bao, Xu-Bin, Huan, Xia-Juan, Wang, Tong-Yan, Zhang, Ao, Miao, Ze-Hong, He, Jin-Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352467/
https://www.ncbi.nlm.nih.gov/pubmed/35907292
http://dx.doi.org/10.1016/j.neo.2022.100823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352467/
https://www.ncbi.nlm.nih.gov/pubmed/35907292
http://dx.doi.org/10.1016/j.neo.2022.100823

Ejemplares similares